Effects of Tibolone and PPARα-agonist on HDL Metabolism in Postmenopausal Women (TibFen)

NCT00809068 Phase 4 COMPLETED

Tibolone (Livial) has been shown in previous studies to lower HDL cholesterol by up to 40%. This study aims to study the effects of fenofibrate on HDL and subfractions in women taking tibolone.

Details

Lead sponsor	Keogh Institute for Medical Research
Phase	Phase 4
Status	COMPLETED
Enrolment	20
Start date	2005-08
Completion	2009-10

Conditions

• HDL Cholesterol

Interventions

• fenofibrate and tibolone
• tibolone

Primary outcomes

• HDL subpopulation analysis — August 2009

Countries

Australia